We found that along with decreased IL-6 and TNF-α, matrine inhibited increases in HMGB1 in CRC, suggesting that HMGB1 and HMGB1 signaling may be relevant targets for CRC treatment. Here, HMGB1 is linked to colorectal carcinoma.